While GSK's vaccine was the first RSV vaccine to be approved by European and U.S. authorities in 2023 for older adults, it has since lagged behind rivals and sales have fallen sharply.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The EU's health regulator is expected to decide in the first half of 2026 on the expanded use of Arexvy, GSK said, adding that it was working on making similar applications to U.S. and Japanese ...